Research delivers insight into the Multiple Myeloma (Kahler Disease) - Pipeline Review, H2 2016

Multiple Myeloma (Kahler Disease) - Pipeline Review, H2 2016 is a new market research publication announced by Reportstack. This report provides an overview of the Multiple Myeloma (Kahler Disease) (Oncology) pipeline landscape.

Multiple myeloma is a type of cancer that is caused by malignant plasma cells that proliferate in the bone marrow and produce abnormally high amounts of a special protein. The exact cause of multiple myeloma is not clear. Multiple myeloma mainly affects older adults. Symptoms include anemia, bleeding, nerve damage, skin lesions, bone tenderness or pain and kidney failure. Treatment includes chemotherapy, radiation, immunosuppression, and surgery.

Complete report available @ Multiple Myeloma (Kahler Disease) - Pipeline Review, H2 2016

Report Highlights

The Pharmaceutical and Healthcare latest pipeline guide Multiple Myeloma (Kahler Disease) – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Multiple Myeloma (Kahler Disease) (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Multiple Myeloma (Kahler Disease) (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Multiple Myeloma (Kahler Disease) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 11, 61, 60, 2, 114, 22 and 2 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 6, 8, 18 and 6 molecules, respectively.

Multiple Myeloma (Kahler Disease) (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Multiple Myeloma (Kahler Disease) (Oncology).
- The pipeline guide reviews pipeline therapeutics for Multiple Myeloma (Kahler Disease) (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources. 
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Multiple Myeloma (Kahler Disease) (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Multiple Myeloma (Kahler Disease) (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects. 
- The pipeline guide reviews latest news related to pipeline therapeutics for Multiple Myeloma (Kahler Disease) (Oncology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Multiple Myeloma (Kahler Disease) (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Multiple Myeloma (Kahler Disease) (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Companies Mentioned

4SC AG AB Science SA AbbVie Inc Ablynx NV Acceleron Pharma Inc Acetylon Pharmaceuticals Inc Actinium Pharmaceuticals Inc Active Biotech AB Adaptimmune Therapeutics Plc ADC Therapeutics Sarl Aduro BioTech Inc Aeglea BioTherapeutics Inc Affimed GmbH AIMM Therapeutics BV Alissa Pharma Altor BioScience Corp Amgen Inc Anthera Pharmaceuticals Inc APIM Therapeutics AS APO-T BV Arcarios BV Arno Therapeutics Inc Array BioPharma Inc Arvinas Inc Asana BioSciences LLC Astellas Pharma Inc Astex Pharmaceuticals Inc AstraZeneca Plc Atara Biotherapeutics Inc Aurigene Discovery Technologies Ltd Bayer AG Bellicum Pharmaceuticals Inc BeyondSpring Pharmaceuticals Inc Biotest AG bluebird bio Inc Boston Biomedical Inc Bristol-Myers Squibb Company Calithera Biosciences Inc Celgene Corp Cell Source Inc Cellectar Biosciences Inc Cellectis SA Cellerant Therapeutics Inc Celleron Therapeutics Ltd CellProtect Nordic Pharmaceuticals AB Celyad SA Chong Kun Dang Pharmaceutical Corp Chugai Pharmaceutical Co Ltd Cleave Biosciences Inc Constellation Pharmaceuticals Inc Curis Inc Cyclacel Pharmaceuticals Inc Daiichi Sankyo Company Ltd DC Prime BV Eli Lilly and Company Enceladus Pharmaceuticals BV Exelixis Inc F. Hoffmann-La Roche Ltd Five Prime Therapeutics Inc Gamida Cell Ltd Genenta Science srl GlaxoSmithKline Plc Glenmark Pharmaceuticals Ltd Gliknik Inc GlycoMimetics Inc GlyTR Therapeutics Inc GP Pharm SA Heidelberg Pharma GmbH Hutchison MediPharma Ltd IGF Oncology LLC ImmunGene Inc Immunomedics Inc Incyte Corp Inflection Biosciences Ltd Inventiva Jasco Pharmaceuticals LLC Johnson & Johnson Juno Therapeutics Inc JW Pharmaceutical Corp Kancera AB Karus Therapeutics Ltd Karyopharm Therapeutics Inc Kesios Therapeutics Ltd Kite Pharma Inc LG Life Science LTD MediGene AG MedImmune LLC Medivation Inc Merck & Co Inc Mesoblast Ltd Millennium Pharmaceuticals Inc MimiVax LLC Molecular Partners AG Molecular Templates Inc MolMed SpA MorphoSys AG Nippon Kayaku Co Ltd Nordic Nanovector ASA Novartis AG Noxxon Pharma AG Oncodesign SA Oncolytics Biotech Inc Onconova Therapeutics Inc OncoPep Inc Oncopeptides AB Ono Pharmaceutical Co Ltd OXIS International Inc Peptinov SAS Pfizer Inc Pharma Mar SA Phylogica Ltd Polyphor Ltd Prescient Therapeutics Ltd Progenra Inc Quimatryx SL RedHill Biopharma Ltd Rhizen Pharmaceuticals SA Sanofi Seattle Genetics Inc Sellas Inc Selvita SA Senhwa Biosciences Inc Sorrento Therapeutics Inc Spectrum Pharmaceuticals Inc Sphaera Pharma Pvt Ltd Stemline Therapeutics Inc Sumitomo Dainippon Pharma Co Ltd Surface Oncology Inc Sutro Biopharma Inc Taiho Pharmaceutical Co Ltd TaiRx Inc Takeda Pharmaceutical Company Ltd Targazyme Inc TeneoBio Inc Terpenoid Therapeutics Inc Teva Pharmaceutical Industries Ltd Theravectys SA TRACON Pharmaceuticals Inc Tragara Pharmaceuticals Inc Transgene Biotek Ltd Trillium Therapeutics Inc Vaccibody AS Vaxil Bio Therapeutics Ltd Verastem Inc Vichem Chemie Research Ltd Vivolux AB Vyriad Inc XTL Biopharmaceuticals Ltd

Contact:

Debora White

Manager - Marketing

debora@reportstack.com

Ph: +1-888-789-6604

ReportstackMarket Research

###